Table 1.

Baseline patient and lesion characteristics

Variables	Vildagliptin group (n = 10)	Control group (n = 10)	p Value
Men, %	100	80	0.474
Age, years	65.9 ± 10.6	68.3 ± 8.1	0.820
BMI, kg/m2	24.0 ± 4.0	24.0 ± 4.5	0.909
Smoker, %	70	40	0.133
Familial history, %	10	10	1.000
Stable angina, %	100.0	100.0
Revascularization vessel, %			0.409
Right coronary artery, %	31.8	34.6
Left main coronary trunk, %	18.2	7.7
Left anterior descending coronary artery, %	31.8	34.6
Left circumflex coronary artery, %	18.2	23.1
Medication, %
Beta blocker, %	70.0	50.0	0.649
ACE-I/ARB, %	50.0	50.0	1.000
Statin, %	90.0	100.0	1.000
Other oral DM drugs, % (except DPP-4 inhibitors)	0.0	0.0
Insulin, %	0.0	0.0
Prasugrel, %	40.0	60.0	0.656
Clopidogrel, %	60.0	40.0	0.656
Aspirin, %	100.0	100.0	0
Laboratory data
LDL cholesterol, mg/dl	84.0 ± 14.3	82.9 ± 27	0.791
HDL cholesterol, mg/dl	47.4 ± 14.8	41.5 ± 9.8	0.289
Triglyceride, mg/dl	118.4 ± 52.1	131.6 ± 77.9	0.939
Creatinine, mg/dl	0.8 ± 0.1	0.9 ± 0.3	1.000
1,5 AG, μg/ml	19.9 ± 4.1	22.0 ± 4.1	0.377
HbA1c (NGSP), %	5.9 ± 0.3	5.9 ± 0.4	0.845
HOMA R	1.5 ± 5.7	1.5 ± 0.6	0.909
CRP, mg/dl	0.2 ± 0.4	0.2 ± 0.2	0.879
75 g OGTT
Fast glucose, mg/dl	97.2 ± 9.0	94.2 ± 11.9	0.471
2-h glucose, mg/dl	185.7 ± 36.6	169.5 ± 20.5	0.405
Fast IRI, μU/ml	6.6 ± 3.5	6.3 ± 2.7	1.000
2-h IRI, μU/ml	114.1 ± 80.3	101.3 ± 75.6	0.791

Mean ± standard deviation (n) for continuous variables; frequency count (%) for categorical variables 1,5 AG = 1,5 anhydroglucitol; 75 g OGTT = 75 g oral glucose tolerance test; ACE-I = angiotensin converting enzyme-inhibitor; ARB = angiotensin II receptor blocker; BMI = body mass index; CRP = C-reactive protein; DM = diabetes mellitus; DPP-4 = dipeptidyl peptidase-4; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; HOMA R = homeostasis model assessment ratio; IRI = immunoreactive insulin; LDL = low-density lipoprotein; NGSP = national glycohemoglobin standardization program